RGEN · XBRL financial data

Repligen financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cost of goods and services sold	157	279	346	354	360	352
Research and development	20	34	44	43	43	54
Selling, general and administrative	120	184	216	219	263	291
Operating income (loss)	70	167	225	48	(35)	55
Interest expense	12	13	1	2	21	22
Other income (expense)	(0)	(1)	(10)	8	(5)	3
Income tax expense (benefit)	(1)	25	33	21	(2)	13
Net income (loss)	60	128	186	36	(26)	49
Earnings per share, basic USD per share	1.14	2.33	3.35	0.64	(0.46)	0.87
Earnings per share, diluted USD per share	1.11	2.24	3.24	0.63	(0.46)	0.86
Weighted average shares, basic millions of shares	53	55	0	0	0	0
Weighted average shares, diluted millions of shares	54	57	0	0	0	0

Fiscal years (RGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	717	604	523	751	757	566
Marketable securities	—	—	—	—	0	202
Accounts receivable	71	117	116	124	134	159
Inventory	95	184	238	202	143	170
Prepaid and other current assets	19	26	20	34	32	41
Total current assets	902	932	998	1,111	1,066	1,137
Property and equipment, net	67	125	191	207	198	187
Right-of-use asset	25	102	125	116	135	120
Goodwill	618	860	856	987	1,031	1,114
Total assets	1,903	2,358	2,525	2,831	2,830	2,950
Accounts payable	17	36	28	20	32	30
Accrued liabilities	53	75	71	57	62	79
Total current liabilities	319	375	404	165	127	136
Lease liability, non-current	26	102	131	127	146	126
Total liabilities	374	608	614	866	857	844
Retained earnings	66	194	397	433	407	456
Total stockholders' equity	1,529	1,750	1,911	1,965	1,973	2,106
Total liabilities and equity	1,903	2,358	2,525	2,831	2,830	2,950
Common shares outstanding (cover page) millions of shares	55	55	56	56	56	56

Fiscal years (RGEN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	60	128	186	36	(26)	49
Stock-based compensation	17	28	27	26	48	33
Net cash from operating activities	63	119	172	114	175	117
Purchases of property and equipment	22	67	85	36	26	24
Net cash from investing activities	(201)	(221)	(233)	(123)	(86)	(298)
Proceeds from issuing common stock	298	0	0	—	—	—
Share repurchases	—	0	0	14	0	0
Net cash from financing activities	306	1	(13)	249	(83)	(15)
Net change in cash	180	(113)	(80)	228	6	(191)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.